Current Report Filing (8-k)
September 30 2021 - 4:44PM
Edgar (US Regulatory)
0001602078
false
0001602078
2021-09-24
2021-09-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of Report (Date of earliest event reported): September 24, 2021
NEMAURA MEDICAL INC.
(Exact name of registrant as specified in charter)
Nevada
(State or other jurisdiction of incorporation)
001-38355
|
|
46-5027260
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
57 West 57th Street
Manhattan, NY
|
10019
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
Registrant’s telephone number, including area code:
|
+1 (646) 416-8000
|
N/A
(Former name or former
address, if changed since last report)
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange
Act (17 CFR 240.14a-12(b))
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
NMRD
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into Material Definitive Agreement.
On September 24, 2021, Nemaura Medical Inc. (the “Company”)
entered into that certain Licence, Supply and Distribution Agreement (the “Agreement”), dated as of September 17, 2021, by
and between the Company and MySugarWatch Duopack Limited (“MSW”). Pursuant to the terms of the Agreement, the Company appointed
MSW as its exclusive global licensee and distributor with regard to the Company’s sugarBEAT® non-invasive continuous glucose
monitor devices and sensors (the “Products”), to be provided solely as duo-packs with prescription only medicines that are
widely prescribed for Type 2 diabetes (each, a “Combination Pack”).
Pursuant to the terms of the Agreement, the Company
agreed to supply the Products in accordance with the terms of the Agreement, and MSW agreed to purchase Products for its own account for
resale.
The Agreement has an initial term of 10 years, subject
to earlier termination pursuant to the terms of the Agreement. Either party may terminate the Agreement at the end of the initial term
upon 12 months’ notice. If not such notice is provided, the Agreement will automatically continue after the initial 10-year term
until terminated by either party giving at least 12 months' prior written notice.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of
the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
NEMAURA MEDICAL INC.
|
|
|
|
By:
|
/s/ Dewan F. H. Chowdhury
|
|
|
Dewan F. H. Chowdhury
Chief Executive Officer
|
Date: September 30, 2021
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024